CN101703662B - Oral Chinese medicament for treating hyperosteogeny - Google Patents
Oral Chinese medicament for treating hyperosteogeny Download PDFInfo
- Publication number
- CN101703662B CN101703662B CN2009101854696A CN200910185469A CN101703662B CN 101703662 B CN101703662 B CN 101703662B CN 2009101854696 A CN2009101854696 A CN 2009101854696A CN 200910185469 A CN200910185469 A CN 200910185469A CN 101703662 B CN101703662 B CN 101703662B
- Authority
- CN
- China
- Prior art keywords
- radix
- raw
- hyperosteogeny
- oral chinese
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an oral Chinese medicament for treating hyperosteogeny, which comprises the following components of raw materials by mass: 45 to 55g of ground beeltle, 25 to 35g of raw peach seed, 25 to 35g of safflower, 25 to 35g of Chinese angelica, 25 to 35g of danshen root, 25 to 35g of cinnamomvine, 25 to 35g of raw frankincense, 25 to 35g of raw myrrh, 25 to 35g of dipsacus asper, 25 to 35g of barbary wolfberry fruit, 25 to 35g of stir-fried eucommia bark, 25 to 35g of Chinese taxillus twig, 25 to 35g of medicinal cyathula root, 25 to 35g of common floweringquince fruit, 25 to 35g of cassia twig and 25 to 35g of halite. The oral Chinese medicament has the effects of tonifying the kidney, activating the blood circulation and removing obstruction in channels to relieve pain, and has the excellent curative effect of treating the hyperosteogeny and protrusion of lumbar vertebral disc.
Description
Technical field
The present invention relates to the field of Chinese medicines, specifically is a kind of oral Chinese medicine for the treatment of hyperosteogeny.
Background technology
Bone matrix hyperplasia is called hyperplastic osteoarthritis, osteoarthritis (OA), degenerated arthrosis, senile arthritis, hypertrophiarthritis again, be because soft tissue degeneration, degenerations such as the cartilage in formation joint, intervertebral disc, ligaments, the edge, joint forms bony spur, variations such as synovial membrane plumpness, and osteoclasia appears, cause insecondary hyperosteogeny, cause joint deformity, when being subjected to abnormal load, cause arthralgia, a kind of disease of symptoms such as limitation of activity.Divide two kinds of constitutional and Secondary cases.Hyperosteogeny is a kind of frequently-occurring disease, commonly encountered diseases.Bone matrix hyperplasia is person in middle and old age's commonly encountered diseases, a frequently-occurring disease.About the name of this disease, both at home and abroad to ununified.External main called after osteoarthritis, osteoarthritis, hyperplastic osteoarthritis, degeneration osteoarthritis; The main name of China's medical science has osteoarthritis, intervertebral disc degeneration, proliferative arthritis, osteoarthrosis degenerative disease etc.; Motherland's medical science then belongs to the scope of arthromyodynia.
Summary of the invention
The invention provides a kind of oral Chinese medicine for the treatment of hyperosteogeny, have the kidney invigorating, invigorate blood circulation, the effect of removing obstruction in the collateral to relieve pain, treatment hyperosteogeny, prolapse of lumbar intervertebral disc are had better curative effect.
Technical scheme of the present invention is:
A kind of oral Chinese medicine for the treatment of hyperosteogeny is characterized in that: each raw material components is by weight than being: Eupolyphaga Seu Steleophaga 45-55, raw peach kernel 25-35, Flos Carthami 25-35, Radix Angelicae Sinensis 25-35, Radix Salviae Miltiorrhizae 25-35, Rhizoma Dioscoreae 25-35, Olibanum 25-35, Myrrha 25-35, Radix Dipsaci 25-35, Fructus Lycii 25-35, Cortex Eucommiae (parched) 25-35, Herba Taxilli 25-35, Radix Cyathulae 25-35, Fructus Chaenomelis 25-35, Ramulus Cinnamomi 25-35, Halitum 15-25.
Described oral Chinese medicine is characterized in that: each raw material components is by weight than being: Eupolyphaga Seu Steleophaga 50, raw peach kernel 30, Flos Carthami 30, Radix Angelicae Sinensis 30, Radix Salviae Miltiorrhizae 30, Rhizoma Dioscoreae 30, Olibanum 30, Myrrha 30, Radix Dipsaci 30, Fructus Lycii 30, Cortex Eucommiae (parched) 30, Herba Taxilli 30, Radix Cyathulae 30, Fructus Chaenomelis 30, Ramulus Cinnamomi 30, Halitum 20.
Eupolyphaga Seu Steleophaga of the present invention has the effect of eliminating stagnation removing blood stasis with potent drugs and reuniting the fractured tendons and bones; Described Semen Persicae, Flos Carthami, Radix Angelicae Sinensis and Radix Salviae Miltiorrhizae have the effect of promoting blood circulation to remove obstruction in the collateral and stasis-dispelling and pain-killing; Described Rhizoma Dioscoreae has the effect of kidney tonifying and spleen invigorating; Described Olibanum and Myrrha have the effect of promoting blood circulation and stopping pain; Described Radix Achyranthis Bidentatae, Herba Taxilli, Radix Dipsaci, the Cortex Eucommiae, Halitum, Fructus Lycii have the effect of the kidney invigorating, bone strengthening pain relieving, promoting blood circulation to remove obstruction in the collateral, symplectic bone; Described Fructus Chaenomelis, Ramulus Cinnamomi, Radix Achyranthis Bidentatae have the effect of expelling wind and removing dampness, promoting blood circulation and stopping pain.
The specific embodiment
A kind of oral Chinese medicine for the treatment of hyperosteogeny comprises Eupolyphaga Seu Steleophaga 50g, raw peach kernel 30g, Flos Carthami 30g, Radix Angelicae Sinensis 30g, Radix Salviae Miltiorrhizae 30g, Rhizoma Dioscoreae 30g, Olibanum 30g, Myrrha 30g, Radix Dipsaci 30g, Fructus Lycii 30g, Cortex Eucommiae (parched) 30g, Herba Taxilli 30g, Radix Cyathulae 30g, Fructus Chaenomelis 30g, Ramulus Cinnamomi 30g, Halitum 20 grams.
Usage: each raw material components is mixed, be ground into smalls, cross 200 mesh sieves, water is general to be ball, a twice-daily, each every clothes 6-9 gram.
Embodiment:
Zhang, man, 37 years old, December was examined on the 1st in 1991, and patient's soreness of waist, profound several months are surplus, and to the lower limb radiation, many places are sought medical advice invalid, the film making prompting: hyperosteogeny, oral Chinese medicine of the present invention for oral administration, logotype is surplus April, and lumbago is ended, and follows up a case by regular visits to not recurrence in 2 years.
Zhang, woman, 50 years old, on November 1st, 1988 examined, and patient's lumbago 1 year is surplus, inscribes lumbago, to the lower limb radiation, the unable to move around that crouches night, pain very need be held battle and be walked, and CT shows: lumbar vertebra hyperosteogeny.Oral Chinese medicine of the present invention for oral administration, logotype is surplus April, and lumbago is ended.Following up a case by regular visits to 2 years pain does not recur.
Claims (2)
1. oral Chinese medicine for the treatment of hyperosteogeny, it is characterized in that: each raw material components is by weight than being: Eupolyphaga Seu Steleophaga 45-55, raw peach kernel 25-35, Flos Carthami 25-35, Radix Angelicae Sinensis 25-35, Radix Salviae Miltiorrhizae 25-35, Rhizoma Dioscoreae 25-35, Olibanum 25-35, Myrrha 25-35, Radix Dipsaci 25-35, Fructus Lycii 25-35, Cortex Eucommiae (parched) 25-35, Herba Taxilli 25-35, Radix Cyathulae 25-35, Fructus Chaenomelis 25-35, Ramulus Cinnamomi 25-35, Halitum 15-25.
2. oral Chinese medicine according to claim 1 is characterized in that: each raw material components is by weight than being: Eupolyphaga Seu Steleophaga 50, raw peach kernel 30, Flos Carthami 30, Radix Angelicae Sinensis 30, Radix Salviae Miltiorrhizae 30, Rhizoma Dioscoreae 30, Olibanum 30, Myrrha 30, Radix Dipsaci 30, Fructus Lycii 30, Cortex Eucommiae (parched) 30, Herba Taxilli 30, Radix Cyathulae 30, Fructus Chaenomelis 30, Ramulus Cinnamomi 30, Halitum 20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101854696A CN101703662B (en) | 2009-11-13 | 2009-11-13 | Oral Chinese medicament for treating hyperosteogeny |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101854696A CN101703662B (en) | 2009-11-13 | 2009-11-13 | Oral Chinese medicament for treating hyperosteogeny |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101703662A CN101703662A (en) | 2010-05-12 |
| CN101703662B true CN101703662B (en) | 2011-04-06 |
Family
ID=42373959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101854696A Expired - Fee Related CN101703662B (en) | 2009-11-13 | 2009-11-13 | Oral Chinese medicament for treating hyperosteogeny |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101703662B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432472B (en) * | 2013-08-15 | 2015-04-08 | 孙江涛 | Chinese medicine decoction for treating knee joint pain associated with hydrops |
| CN104940520B (en) * | 2015-06-12 | 2018-06-19 | 公安县中医医院 | A kind of granule for treating pain in waist and lower extremities |
| CN105168758A (en) * | 2015-11-03 | 2015-12-23 | 孙熙 | Medicine for treating hyperostosis |
| CN105709018A (en) * | 2016-04-29 | 2016-06-29 | 历娜 | Traditional Chinese medicine composition for treating prolapse of lumbar intervertebral disc |
| CN106491882A (en) * | 2016-12-26 | 2017-03-15 | 广西中医药大学 | A kind of Yao medicinal composition and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150910A (en) * | 1996-04-18 | 1997-06-04 | 花茂时 | Osteophytosis pill and its compounding method |
-
2009
- 2009-11-13 CN CN2009101854696A patent/CN101703662B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150910A (en) * | 1996-04-18 | 1997-06-04 | 花茂时 | Osteophytosis pill and its compounding method |
Non-Patent Citations (1)
| Title |
|---|
| 邓振中等.中医药治疗类风湿性关节炎的研究进展.《云南中医中药杂志》.2008,第29 卷(第9 期),53-55. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101703662A (en) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103156972B (en) | Traditional Chinese medicine combination for treating fracture, hairline fracture and traumatic injury | |
| CN100506274C (en) | Traditional Chinese medicine for treating cervical vertebra disease | |
| CN102091295B (en) | Chinese medicinal composition for treating femoral head necrosis and preparation method thereof | |
| CN104398982A (en) | Traditional Chinese medicine composition for treating traumatic injury and joint pain and swelling | |
| CN101703662B (en) | Oral Chinese medicament for treating hyperosteogeny | |
| CN102166277A (en) | Waist healing pill | |
| CN104758659A (en) | Traditional Chinese medicine paste for treating muscle and bone diseases | |
| CN101897879B (en) | Traditional Chinese medicine for treating rheumatic arthritis | |
| CN101690768B (en) | Vein and artery relieving pills for impediment of sinew | |
| CN101496838A (en) | Chinese medicament preparation for treating hyperosteogeny and rheumatism and preparation method thereof | |
| CN104922363A (en) | Traditional Chinese medicine composite for treating osteoproliferation | |
| CN101433698B (en) | Chinese medicament preparation for reunion of bone | |
| CN104107288A (en) | Sinew-relaxing collateral-activating pill | |
| CN103948878B (en) | A kind of Chinese medicine composition for the treatment of osteopathia | |
| CN102579672A (en) | Medicament for treating bone hyperplasia and lumbar disc herniation | |
| CN102552519A (en) | Chinese medicine composition for activating blood and stopping pain, preparation process and application | |
| CN102406870A (en) | Medicament for treating rheumatic arthralgia | |
| CN102430096B (en) | Medicament for treating rheumatic or rheumatoid diseases | |
| CN102038930A (en) | Medicament for treating protrusion of lumbar vertebral disc | |
| CN101518611A (en) | Traditional Chinese medicine for treating bone tumor | |
| CN102836346B (en) | Traditional Chinese medicine for treating lumbar disc herniation | |
| CN102872287A (en) | Traditional Chinese medicine composition for treating femoral head necrosis and preparation method thereof | |
| CN103007236B (en) | Chinese medicinal composition for treating ankylosing spondylitis | |
| CN101954043A (en) | Medicament for treating hyperosteogeny and preparation method thereof | |
| CN102068534B (en) | Chinese medicinal composition for relaxing tendons and activating collaterals and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110406 Termination date: 20141113 |
|
| EXPY | Termination of patent right or utility model |